Revytal – Retatrutide Research Peptide Pen (30mg / 3ml)
All products are shipped in a cooler box at the appropriate temperature.
What is Retatrutide?
Retatrutide (LY3437943) is a next-generation synthetic peptide and one of the most advanced investigational compounds in current metabolic science. Unlike single or dual receptor agonists, retatrutide simultaneously activates three key metabolic receptors — GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCG) — making it a true triple receptor agonist. This multi-pathway mechanism combines the appetite-suppressing and glucose-regulating properties of GLP-1/GIP agonism with glucagon receptor activation’s capacity to drive energy expenditure, lipolysis, and hepatic fat utilization.
Revytal delivers ultra-high purity retatrutide (>99%, third-party verified) in a convenient, ready-to-use pre-filled pen injector, engineered for investigating next-generation metabolic regulation, multi-hormone signaling, and body composition modulation in research settings.
What are the benefits of Retatrutide in research?
Retatrutide’s unique triple-agonist profile makes it one of the most compelling compounds available for metabolic research. Key areas of investigational interest include:
- Appetite suppression: Retatrutide acts through both central and gastrointestinal mechanisms to significantly reduce caloric intake and promote satiety signaling.
- Glucose homeostasis: The compound supports glucose-dependent insulin secretion and glucagon modulation, contributing to improved glycemic control in research models.
- Energy expenditure: Via glucagon receptor activation, retatrutide demonstrates the potential to meaningfully increase fat oxidation and overall energy expenditure.
- Body weight modulation: Phase 2 clinical data have shown mean body weight reductions of up to approximately 24% over 48 weeks — among the most significant findings reported for any investigational metabolic compound to date.
- Liver fat reduction: Research models have shown decreases in liver fat content of up to 82%, with notable improvements in markers associated with metabolic dysfunction-associated steatotic liver disease (MASLD).
- Cardiometabolic parameters: Investigations have documented favorable shifts in lipid profiles, inflammatory markers, blood pressure, and insulin sensitivity across relevant study models.
- Body composition: Retatrutide research consistently demonstrates improvements in the ratio of lean to fat mass, making it a subject of strong interest for body composition studies.
Clinical Research & Trial Results
Retatrutide has been the subject of rigorous phase 2 clinical investigation. In a landmark dose-ranging trial, participants receiving higher doses of retatrutide achieved mean weight reductions approaching 24% of body weight over a 48-week period — outcomes that have positioned this triple agonist as one of the most potent investigational agents in the GLP-1 class and beyond.
Additional study findings have confirmed retatrutide’s effects on hepatic fat, cardiometabolic risk factors, and glucose regulation, with a safety and tolerability profile consistent with the broader incretin-based drug class. The compound’s advanced fatty diacid conjugation technology contributes to its extended half-life of approximately 6 days, supporting once-weekly administration schedules across research protocols.
Proper Usage & Dosage Guidelines
The dosage and administration of retatrutide for research purposes should be determined according to the specific experimental protocol. Revytal is administered via subcutaneous injection, with retatrutide’s approximately 6-day half-life supporting once-weekly dosing in research settings.
Pen Specifications – Revytal 30mg / 3ml Pen:
The Revytal pen contains 30mg of retatrutide in 3ml solution (10mg/ml concentration), offering ample capacity for extended or higher-dose experimental protocols.
Additional Usage Notes:
- Inject into the abdomen area or the front of the thigh
- After injecting, wait 10 seconds before removing the needle
- Rotate injection sites between administrations
- Store refrigerated at all times; do not freeze
- Use sterile, single-use needles only — replace with each injection
Possible Side Effects
As with all peptide compounds, retatrutide research has identified a profile of potential side effects, most commonly associated with GI-related responses. These may include nausea, vomiting, diarrhea, constipation, or mild discomfort at the injection site — effects consistent with those observed across the GLP-1 receptor agonist class. In clinical observations, these effects were most prominent during dose escalation and generally diminished over time.
Adherence to recommended dosing protocols is the most effective means of minimizing adverse responses in research settings.
What’s Included
- Reusable precision peptide pen injector
- Pre-filled Revytal (retatrutide) solution — 30mg / 3ml
- Detailed usage instructions
- 10 sterile, single-use needles
Why Choose Revytal?
Revytal is manufactured in certified laboratories to deliver retatrutide at greater than 99% purity, third-party verified. The ready-to-use pre-filled pen format offers a sterile, precise, and lab-friendly experience designed for researchers who demand consistency and reliability. Advanced fatty diacid conjugation ensures prolonged compound stability and extended action, maximizing the utility of every research session.
Push the boundaries of incretin-based and triple-agonist research with Revytal — where triple-hormone synergy meets unmatched potency in metabolic investigation.
The information presented has been collected from published studies and analyses and is not intended for diagnosing, treating, or preventing any disease.
Notice: Revytal (retatrutide) is supplied exclusively for in-vitro laboratory research, scientific experimentation, and analytical purposes only. It is not a pharmaceutical product, dietary supplement, or compound intended for human or veterinary use, consumption, diagnosis, treatment, or any medical application whatsoever. The purchaser is solely responsible for safe handling, appropriate storage, and full compliance with all applicable laws, regulations, and institutional guidelines.
Reviews
There are no reviews yet.